FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment

The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare ...
Healio

FDA approves Epioxa for keratoconus

Epioxa is the first epithelium-on cross-linking procedure approved in the U.S. Glaukos plans for Epioxa to be commercially ...
Lupus Foundation of America

FDA Approves Gazyva® (obinutuzumab) for the Treatment of Adults with Lupus Nephritis

The U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab), developed by Genentech, as a treatment for adults with lupus nephritis (LN), also known as lupus-related kidney disease ...
Ophthalmology Times

Glaukos receives FDA approval for Epioxa topical therapy for keratoconus

Glaukos announced that the FDA has approved the new drug application for its topical drug therapy (Epioxa HD/Epioxa) for keratoconus. 1,2 This approval makes it the first FDA-approved corneal ...
Healio

FDA approves Yuflyma for adolescent hidradenitis suppurativa, pediatric uveitis

The FDA approved expanded indications of Yuflyma and its unbranded version to treat hidradenitis suppurativa in adolescents aged 12 years and older and uveitis in children aged 2 years and older, ...
Dermatology Advisor

Extended Dupilumab Dosing as Effective as Standard Dosing Regimens for AD

Extended dosing of dupilumab in patients with AD has similar efficacy as standard dosing, with no significant affect seen on ocular adverse events.
Ophthalmology Advisor

Foselutoclax Delivers Durable Vision Benefits in Diabetic Macular Edema

Presenters at the AAO discussed phase 2 clinical trial results evaluating the safety and efficacy of foselutoclax (UBX1325) compared with aflibercept in diabetic macular edema.